옵션 체인은 다양한 행사가격과 만기일에 대한 Click Holdings의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Click Holdings에 대한 시장 심리를 평가합니다..

Click Holdings (NASDAQ:CLIK) 주식, 옵션 체인

Click Holdings Ltd is a human resources solutions provider, specializing in offering comprehensive human resources solutions. It is focused on talent sourcing and the provision of temporary and permanent personnel to customers and also in placing professional accountants and company secretaries, registered nurses and healthcare workers as well as other blue-collar workers, for direct hire and contract staffing roles. The Company operates in three segments, 1) professional solution services, 2) nursing solution services and 3) logistic and other solution services. Maximum revenue is generated from Professional solution services and Hong Kong.

Click Holdings Ltd

News

WGRX

Wellgistics Health Announces Preliminary Inclusion In Russell 2000 And Russell 3000 Indexes, As Part Of 2025 Russell US Indexes Annual Reconstitution

<ul>
<li>Strategic Expansion into Turkiye: DeFi Technologies enters collaboration with Misyon Bank and Misyon Kripto to work to introduce ETPs, offering Turkish investors alternative access to digital assets like Bitcoin and Ethereum.</li>
<li>Tapping a High-Growth Market: Turkiye ranks among the top countries in crypto adoption, driven by inflation, currency volatility, and a digitally native population, with over 50% of investor population holding digital assets.</li>
<li>Global Growth Momentum: The partnership aligns with DeFi Technologies' broader strategy to expand across the Middle East, Asia, and Africa through key institutional partnerships and localized product offerings.</li>
</ul>
&nbsp;"DeFi Technologies"(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"),&nbsp; and its subsidiary Valour Inc. ("Valour"), a leading issuer of exchange traded products ("ETPs") that provide simplified access to digital assets, is pleased to announce its strategic collaboration with Misyon Bank and its crypto trading subsidiary Misyon Kripto prepare for introducing a series of innovative digital investment products to Turkish investors.

Contracts

DEFT

DeFi Technologies And Misyon Enters Agreement To Launch Innovative Digital Asset Investment Products In Turkiye

STRM

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

One of the major dealers of Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) has reportedly shut down its operations across multiple cities in China as the company expands into the European market.
What Happened: Over 20 stores of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival in China's eastern Shandong province, owned by a company called Qiancheng Holdings, were shut, according to a Reuters report citing Chinese state-owned media on Thursday.
The company shutting down the stores in over 4 major cities has affected over 1,000 customers with warranty and after-sales service-related woes, the report suggests.
Qiancheng cited changes to BYD's dealer policies, which increased the pressure on the company's cash flow. However, a representative from BYD cited in the Reuters report suggests that Qiancheng's rapid expansion led to the crisis instead.
BYD did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: BYD has been steadily expanding its footprint on the global front, with the automaker setting up <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">a manufacturing facility</a> in Hungary, which can annually produce over 200,000 EVs.
BYD <a href="https://www.benzinga.com/25/05/45564693/byd-outsells-elon-musks-tesla-amid-european-plans-shift-into-gear">also overtook Tesla </a>for the first time in sales in the European market, registering marginally better sales in April 2025 than Elon Musk's company.
However, the Chinese automaker has recently landed in legal trouble as BYD faces a <a href="https://www.benzinga.com/government/regulations/25/05/45639357/teslas-chinese-rival-byd-sued-for-45-million-over-alleged-human-trafficking-slave-like-conditions-at-brazil-factory-site">$45 million lawsuit</a> in Brazil for alleged "human-trafficking" and "slave-like" conditions at the construction site in Brazil's Bahia state.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/05/45611701/chinese-regulators-will-meet-tesla-rival-byd-other-companies-to-discuss-zero-mile-used-cars-report">Chinese Regulators Will Meet Tesla Rival BYD, Other Companies To Discuss &#8216;Zero Mile&#8217; Used Cars: Report</a></li>
</ul>
Photo courtesy: Tada Images/Shutterstock

Asia

Markets

BYDDY

TSLA

Over 20 BYD Dealerships Shut Down In China Amid Expansion To Europe, Impacting 1,000+ Customers: Report

QNTM

Quantum Biopharma Licensee Celly Nutrition Changes Name To Unbuzzd Wellness Inc. Effective May 23, 2025

DA Davidson analyst Tom White upgrades eXp World Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPI#NASDAQ">EXPI</a>) from Neutral to Buy and announces $10.75 price target.

Upgrades

Price Target

Analyst Ratings

EXPI

DA Davidson Upgrades eXp World Holdings to Buy, Announces $10.75 Price Target

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) (CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, that it has hired leading audit firm MNP LLP ("MNP") effective May 20, 2025, to conduct Public Company Accounting Oversight Board ("PCAOB") audits of the Company's financial statements in preparation for a possible initial public offering ("IPO"). The Company's predecessor auditor, Stern &amp; Lovrics LLP (the "Predecessor Auditor") resigned effective May 20, 2025, at the Company's request, and the Company's board of directors, upon the audit committee's recommendation, appointed MNP to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.

CSE:QNTM

Quantum BioPharma's Unbuzzd Wellness Inc. Engages MNP for PCAOB Audits Ahead Of Potential IPO, Replacing Stern & Lovrics

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and raises the price target from $7 to $9.

TSHA

Chardan Capital Maintains Buy on Taysha Gene Therapies, Raises Price Target to $9

Raymond James analyst Srini Pajjuri maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Outperform and lowers the price target from $130 to $110.

MRVL

Raymond James Maintains Outperform on Marvell Tech, Lowers Price Target to $110

Barrington Research analyst Vincent Colicchio maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Outperform and maintains C$2.5 price target.

TSX:ALYA

Barrington Research Maintains Outperform on Alithya Group, Maintains C$2.5 Price Target

Earnings

CORRECTION: Aurora Mobile Q1 Adj. EPADS $(0.06) Down From $(0.04) YoY, Sales $12.26M Up From $8.94M YoY

JetBlue (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) and United (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) today announced Blue Sky: a new and unique collaboration that gives customers of both airlines even more options to find flights that fit their plans as well as new opportunities to earn and use MileagePlus&#xAE; miles and TrueBlue points across both airlines.

JBLU

JetBlue and United Team Up to Expand Flight Options and Shared Rewards

Guidance

ALAR

Alarum Technologies Sees Q2 Sales $7.663M-$8.137M vs $8.35M Est

WIIM

Tesla shares are trading higher after CEO Elon Musk announced his role as Special Government Employee has concluded.

BOSC

BOS CEO Says 'Based on our first quarter performance and contracted backlog, we are optimistic about surpassing our full-year outlook for 2025, which are revenues of $44 million and net income of $2.5 million,'

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) with a Buy and maintains $10 price target.

Reiteration

DMAC

HC Wainwright & Co. Reiterates Buy on DiaMedica Therapeutics, Maintains $10 Price Target

Earnings Misses

Alarum Technologies Q1 Adj. EPADS $0.16, Inline, Sales $7.13M Miss $7.87M Estimate

BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) reported quarterly earnings of $0.23 per share. This is a 76.92 percent increase over earnings of $0.13 per share from the same period last year. The company reported $15.03 million in sales this quarter. This is a 33.13 percent increase over sales of $11.29 million the same period last year.

BOS Better Online Solns Q1 EPS $0.23 Up From $0.13 YoY, Sales $15.03M Up From $11.29M YoY

Telsey Advisory Group analyst Dana Telsey maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Outperform and maintains $125 price target.

Telsey Advisory Group Maintains Outperform on Abercrombie & Fitch, Maintains $125 Price Target

Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical trial will proceed. The U.S. Food and Drug Administration (FDA) previously reviewed and authorized the protocol to proceed under the Company's Investigational New Drug (IND) application. The study will evaluate the efficacy and safety of&nbsp;IHL-42X, Incannex's lead asset for the treatment of&nbsp;obstructive sleep apnea (OSA)—a condition affecting an estimated one billion people globally with no approved oral pharmaceutical therapy.
With the FDA authorization in place, Incannex will initiate&nbsp;Phase 3 immediately&nbsp;following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency and speed.

IXHL

Incannex Healthcare To Proceed Phase 3 Component Of RePOSA Clinical Trial Following FDA Authorization

Press Releases

Click Holdings Limited Announces Closing of Initial Public Offering

Click Holdings Limited Reports Strong Growth in the First Half of 2024 Financial Results

General

CLICK announced to expand service to the Community Care Service Voucher scheme for elderly (CCSV scheme) in Hong Kong

Click announced the CEO Statement

CLIK Announces Strategic Acquisition of Leading Nursing Care Competitor, Expanding Market Presence and Talent Pool

CLIK Announces Pricing of $8.28 Million Public Offering of Ordinary Shares

CLIK Announces Closing of $8.28 Million Public Offering of Ordinary Shares

CLIK Announces Acquisition of Remaining 75% Equity Interest in Leading Nursing Care Competitor, Solidifying Market Leadership and Expanding Revenue Base

CLIK announces to collaborate with an advanced technology company under the Tencent SSV initiatives, to jointly promote 24-hour instant device service for senior citizens in Hong Kong; and also announces change to board composition

Peraso Inc. (NAS: PRSO) Surging on 2M mmWave Milestone, Defense & Satellite Boost – DKS, FL, HIT, CLIK News Inside

Comments

Click Holdings

Click Holdings (CLIK) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌